Biotech Values

[urche]

Thanks, Regulardoc, for your estimates of various enoxaparin doses. As another hospital based internist, I think your figures seem right on.
I'll make a prediction that we will be seeing a modest increase in utilization of enoxaparin driven by lower cost. The reason is increasing evidence that the risk of developing DVT doesn't end when a patient is discharged. Out of sight, but not out of risk. Orthopedic patients often get prophylaxis for 3 wks after surgery in the area I work. But, medical patients , based on the evidence , especially the frail and semi-ambulatory, should probably also be getting anticoagulation for up to a month after acute illness. So, to the extent that lower price will drive utilization in that underserved niche, I think there is reason to think we will see increased utilization of the 30 and 40 mg daily dosage.

Urche (in Vt/NH)